Enzo Biochem (NYSE:ENZ) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Enzo Biochem (NYSE:ENZGet Free Report) in a report issued on Thursday. The brokerage set a “hold” rating on the medical research company’s stock.

Enzo Biochem Trading Up 1.6 %

Shares of NYSE:ENZ opened at $0.71 on Thursday. The company has a 50-day moving average price of $0.99 and a two-hundred day moving average price of $1.07. Enzo Biochem has a twelve month low of $0.68 and a twelve month high of $1.50.

Enzo Biochem (NYSE:ENZGet Free Report) last posted its quarterly earnings results on Monday, December 16th. The medical research company reported ($0.05) EPS for the quarter. Enzo Biochem had a negative return on equity of 11.84% and a negative net margin of 81.73%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. XTX Topco Ltd raised its holdings in Enzo Biochem by 94.5% during the 2nd quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company’s stock valued at $31,000 after buying an additional 13,735 shares during the last quarter. BBR Partners LLC bought a new position in shares of Enzo Biochem during the third quarter valued at about $112,000. Geode Capital Management LLC boosted its holdings in shares of Enzo Biochem by 3.3% during the third quarter. Geode Capital Management LLC now owns 368,646 shares of the medical research company’s stock worth $413,000 after purchasing an additional 11,742 shares during the period. Finally, Renaissance Technologies LLC grew its stake in shares of Enzo Biochem by 2.6% in the second quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company’s stock worth $2,725,000 after purchasing an additional 64,417 shares during the last quarter. 36.90% of the stock is currently owned by institutional investors.

About Enzo Biochem

(Get Free Report)

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.

Read More

Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.